Dados B3 › TXRX4 × AMER3
TXRX4 × AMER3
Indicators
Each row uses the most recent year in which BOTH companies have the figure, and says which year that is. A cell with ! carries a caveat — hover to read it. We do not name a winner: that would be a recommendation, and this site does not give any.
| indicator | TXRX4 | AMER3 | year |
|---|---|---|---|
| ROE | — | -5.6% | no year where both have it |
| ROIC | — | 3.4% | no year where both have it |
| ROA | -32.8% | -1.6% | 2025 |
| Gross margin | 21.2% | 27.0% | 2025 |
| EBIT margin | -8.1% | 2.7% | 2025 |
| Net margin | -49.3% | -2.2% | 2025 |
| Net debt/EBITDA | — | 0.83x | no year where both have it |
| Current ratio | 0.38x | 1.67x | 2025 |
| Revenue growth (1y) | -1.5% | -1.2% | 2025 |
| Revenue growth (5y CAGR) | 6.8% | 4.0% | 2025 |
| Piotroski F-Score | 4/9 | 3/9 | 2025 |
Point-in-time multiples
Priced at the first session on or after the day each filing became public — never the period close.
| indicator | TXRX4 | AMER3 | year |
|---|---|---|---|
| P/E | -0.00x | -3.81x | 2025 |
| P/B | — | 0.22x | 2025 |
| EV/EBITDA | — | 1.73x | 2025 |
| FCF yield | — | 34.5% | 2025 |
Numbers on this page are live. Data version 2026-09-01-supressao-declarada · page generated 2026-09-09 15:45 UTC. If this does not match /saude, you are reading a cached copy.
Sources: CVM (open data, ODbL) and B3 (COTAHIST). Not affiliated with B3 or the CVM. Not investment advice.